|Videos|August 31, 2022
Case 1: 2-Year-Old Male With Atopic Dermatitis
Dr Joshua Zeichner reviews the case of a 2-year-old patient with atopic dermatitis.
Advertisement
Episodes in this series
Joshua Zeichner, MD: Here’s case No. 1. This is a 2-year-old boy previously diagnosed with moderate atopic dermatitis. He presents to his dermatologist with worsening of red, dry, itchy patches on his arms. The family has taken the child to the pediatrician, who recommended over-the-counter agents. The irritation and redness improved initially, but after 3 months, the patient experienced a flare. The family was then referred to the dermatologist for the next steps.
Transcript edited for clarity
Advertisement
Related to this article
SYX-5219 improved disease severity and itch in a Phase 1b trial of adults with moderate to severe atopic dermatitis.
Christophe Piketty discusses 3-year ARCADIA data demonstrating sustained efficacy and long-term safety of nemolizumab in atopic dermatitis.
No skin lesion flares were observed through 16 weeks after switching from dupilumab to upadacitinib; itch flares occurred in 3.6% to 4.8% of patients with baseline WP-NRS scores of 6 or lower.
Three-year ARCADIA LTE data show sustained skin clearance and itch control with nemolizumab in moderate-to-severe atopic dermatitis.
Upadacitinib showed broader inflammatory effects and earlier skin barrier restoration than dupilumab in atopic dermatitis.
Advertisement
Advertisement
Trending on Dermatology Times
1
Social Media Mythbusters: Can Castor Oil Really Grow Hair?
2
EADV 2026 Atopic Dermatitis Highlights: Tilrekimig, RAC2 Inhibition, and Level Up Data
3
FDA Approves Pritelivir for Refractory Mucocutaneous HSV in Immunocompromised Adults
4
GLP-1 Agonists Address Metabolic Risk in Psoriatic Disease
5